Researchers in Prof. Mark Kay's laboratory have developed variant AAV (adeno-associated virus) vectors with specificity and high transduction efficiency for pancreatic alpha- and beta- islet cells.
Stanford researchers have invented a method and developed compositions of matter to reduce the production of infectious viruses in cells that line the respiratory tract. The invention enables the use of gene-silencing approaches to prevent and treat viral infections.
Stanford researchers have developed a method for assessing neonatal health risk by using longitudinal electronic health records (EHR) utilizing a machine learning model comprising deep learning neural networks.
Stanford researchers have developed a data sketching method that leverages neural networks to perform queries on large datasets. As datasets grow larger and more complex, they must be compacted (sketched) in ways such that they are easily stored and processed.
Stanford scientists have invented a new suite of adaptable hydrogel biomaterials that are optically transparent and injectable for cell encapsulation, tissue engineering, and drug delivery.
A major barrier in CAR-T cell therapies has been T cell exhaustion, which affects the durability and effectiveness of treatments, particularly for solid tumors.
The Hu Lab at Stanford has developed a neuroprotective gene therapy for treating glaucoma and other optic neuropathies. Their gene therapy AAV vector expresses NMNAT2 operably linked to a retinal ganglion cell-specific promoter (mSngc).
Stanford inventors in the lab of Dr. Katrin Svensson have discovered an endogenous peptide hormone that shows promise in treating obesity and diabetes.
Researchers at Stanford have developed a methodology for deep learning-based image reconstruction by incorporating the physics or geometry priors of the imaging system with deep neural networks.
SparseGMM, is a new algorithm which is a novel statistical approach for identifying drug targets in cancer patients and other diseases by more accurately modeling biological pathways.
Stanford researchers have developed a novel approach to make a stable and active platinum-alumina catalyst that maintains high activity under harsh conditions.
Stanford researchers have developed a new controllable methodology for molecularly targeted ultrasound contrast agent production with pre-formed ligand-phospholipid bioconjugates.
Stanford inventors have developed a single cell screening platform that can be used to predict the therapeutic effects of osteoarthritis (OA) drugs on individual patients by defining consequent changes in the cellular landscape.